CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Genzyme Corporation (Nasdaq: GENZ - News) announced today that a research study published in the January issue of the Journal of Bone and Mineral Research demonstrates that long-term use of Cerezyme® (imiglucerase for injection) significantly improves bone mineral density in patients with Type 1 Gaucher disease in a dose-dependent manner.
